Lv1
48 积分 2024-04-25 加入
861-P: Targeting Activin Type II Receptors—Develop Monoclonal Antibodies LAE102, LAE103, and LAE123 as Candidate Therapeutics for Muscle Growth and Fat Reduction
1天前
求助中
Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers
4天前
已完结
Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial
4天前
已完结
The story of amylin: from physiology to therapy
14天前
已完结
Scientific white paper on concentration-QTc modeling
1个月前
已完结
Supporting an integrated QTc risk assessment using the hERG margin distributions for three positive control agents derived from multiple laboratories and on multiple occasions
1个月前
已完结
Neuronal FAM171A2 mediates α-synuclein fibril uptake and drives Parkinson’s disease
1个月前
已完结
Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the Phase 3 clinical trials BaxHTN, BaxAsia, and Bax24
1个月前
已完结
Novel IRAK4 Inhibitors for Treating Asthma, COPD, Cancer, Autoinflammatory Diseases, and Autoimmune Diseases
2个月前
已完结
Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases
2个月前
已完结
皖公网安备34019202002308
